Tissue Dynamics and Galmed Pharmaceuticals have identified a previously unrecognized metabolic pathway responsible for cardiac fibrosis and heart failure using a human cardiac organoid model. Their preclinical study demonstrated that a combination of Aramchol Meglumine (an SCD1 inhibitor) and a selective PPARα agonist significantly reduced fibrotic burden while preserving cardiac muscle integrity and metabolic function in inflammatory human cardiac organoids. This discovery supports the development of Aramchol for cardiac fibrosis and highlights the potential of advanced AI and human organoid models in drug development.

This article compares two healthcare ETFs, State Street Health Care Select Sector SPDR ETF (XLV) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH), highlighting their contrasting investment strategies, costs, and performance. XLV, a market-cap-weighted fund, offers a lower expense ratio, higher dividend yield, and better historical returns. RSPH, an equal-weight fund, provides broader diversification by giving equal impact to all its holdings, regardless of company size.

VeriSign held its annual general meeting where shareholders rejected a proposal for an independent board chairman. Concurrently, the company reported stronger Q1 2026 results and raised its full-year 2026 revenue and operating income guidance. These developments are leading investors to evaluate VeriSign's governance alongside its growth prospects, focusing on its ability to maintain high margins and grow its core .com and .net domain franchise.

Natixis Advisors LLC increased its stake in The Boeing Company by 8.8% in Q4, acquiring an additional 138,924 shares to a total of 1,726,366 shares valued at $374.8 million. Boeing now constitutes 0.5% of Natixis Advisors' portfolio and is its 26th largest holding. The article highlights positive developments for Boeing, including FAA clearance for 737 MAX production ramps and potential China orders, alongside ongoing challenges like its debt load and execution concerns.

Pincus Capital Management LP initiated a new position in Blackstone Inc. during the fourth quarter, acquiring 25,550 shares valued at approximately $3.94 million, making it their 10th-largest holding. This investment comes as Blackstone recently beat Q1 earnings expectations and saw significant insider buying. Analysts currently rate Blackstone as a consensus Hold with an average target price of $151.05.

Natixis Advisors LLC significantly increased its stake in Netflix, Inc. (NASDAQ:NFLX) by 797.3% in the fourth quarter, now holding nearly 5 million shares worth approximately $467.9 million. Other major institutional investors also added to their Netflix holdings, with institutional ownership of the company's stock reaching 80.93%. The company reported strong Q4 earnings, beating analyst estimates for both EPS and revenue, and analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $114.82.

Natixis Advisors LLC increased its stake in Cisco Systems, Inc. ($CSCO) by 0.5% in the fourth quarter, bringing its total holdings to 3,626,922 shares valued at approximately $279.4 million. The company reported strong quarterly results with EPS of $1.06 and revenue of $15.84 billion, exceeding estimates and showing a 12% year-over-year revenue increase. Analysts maintain a "Moderate Buy" rating for Cisco, with several firms raising price targets due to its performance and AI infrastructure momentum.

Galmed Pharmaceuticals and Tissue Dynamics announced positive preclinical results for a combination therapy involving Aramchol Meglumine and a selective PPARα agonist in treating cardiac fibrosis. The study, using human cardiac organoid models, demonstrated a significant reduction in fibrotic burden and highlighted a previously unrecognized metabolic pathway. Galmed's stock surged 15% following the news, and the companies are preparing for IND-enabling activities.

This article identifies top pre-market gainers and losers on Friday, January 5, 2024. It details stock performance, including percentage changes and specific price points for companies like DSS INC, DERMATA THERAPEUTICS INC, GRAPHITE BIO INC, and AGILON HEALTH INC, also noting any recent news or past performance impacting their current trading.

Natixis Advisors LLC reduced its stake in The TJX Companies, Inc. by 1.0% in the fourth quarter, selling 14,205 shares while still holding over 1.4 million shares valued at approximately $217.9 million. This news comes as TJX reported strong quarterly results, beating EPS and revenue expectations, and increased its quarterly dividend. Wall Street analysts generally maintain a "Buy" rating for TJX with a consensus price target of $174.58.